A new study suggests that a drug similar to Viagra could slow cognitive decline in people with early-stage Alzheimer's disease by nearly a third. The experimental medication, AR1001, works by relaxing blood vessels and increasing blood flow to the brain, potentially addressing underlying factors involved in Alzheimer’s progression.
The phase three clinical trial involved 1,535 participants from 13 countries, including the United Kingdom. Half of the participants received AR1001 daily, while the remainder were given a placebo. Researchers monitored changes in memory and cognitive function over the course of one year. The drug demonstrated a statistically significant slowing of decline in 31% of patients who were not taking other Alzheimer’s treatments, a subgroup comprising 604 individuals. However, the overall trial did not show significant benefits across all participants, including those already on standard Alzheimer's medications.
AR1001, developed by South Korean pharmaceutical company AriBio, belongs to a class of drugs known as phosphodiesterase-5 (PDE5) inhibitors. These drugs, which include Viagra, are traditionally used to treat erectile dysfunction and pulmonary arterial hypertension by inhibiting an enzyme that promotes blood vessel constriction. By helping keep blood vessels relaxed, AR1001 enhances cerebral blood flow and may also activate cellular pathways related to learning and memory. Researchers also speculate that it could influence other brain processes involved in Alzheimer's, such as inflammation.
Experts not involved in the trial have described the findings as promising but advise cautious optimism. Tara Spires-Jones, a professor of neurodegeneration at the University of Edinburgh, highlighted the drug’s dual mechanism of improving blood flow and stimulating brain cells, calling the results “very promising.” Dr. Sheona Scales, director of research at Alzheimer’s Research UK, termed the results an “important milestone” and emphasized that AR1001 represents a novel approach compared to existing treatments that primarily target amyloid plaques. She noted the drug’s advantage as an oral once-daily pill that could potentially simplify treatment regimens.
Dr. Richard Oakley, associate director of research and innovation at the Alzheimer’s Society, welcomed the development as a potential disease-modifying therapy that targets causes rather than symptoms of Alzheimer’s. He warned, however, that patients should not attempt to use Viagra itself as a treatment, since AR1001 is specifically engineered and must undergo regulatory approval before being made available. Side effects reported in the trial were mostly mild to moderate.
Alzheimer’s disease, the most common form of dementia, currently affects nearly one million people in the UK and is projected to impact 153 million worldwide by 2050. There is no known cure, and current treatments largely focus on symptom management. The new findings were presented recently at the Clinical Trials on Alzheimer’s Disease conference in Boston, marking a step forward in exploring alternative pathways for addressing this complex disorder.
